HSBC Holdings’s CytomX Therapeutics CTMX Stock Holding History

HSBC Holdings’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$103K	Buy	+26,636	New	+$102K	﹤0.01%	2803
2026 Q1	–	Sell	-12,230	Closed	-$52.1K	–	2967
2025 Q4	$52.1K	Buy	+12,230	New	+$46.5K	﹤0.01%	2863
2021 Q1	–	Sell	-15,890	Closed	-$105K	–	2797
2020 Q4	$105K	Buy	15,890 +3,954	+33%	+$28.2K	﹤0.01%	2944
2020 Q3	$80K	Sell	11,936 -1,899	-14%	-$14.1K	﹤0.01%	2648
2020 Q2	$115K	Sell	13,835 -683	-5%	-$6.34K	﹤0.01%	2498
2020 Q1	$111K	Buy	14,518 +2,582	+22%	+$18K	﹤0.01%	2455
2019 Q4	$99K	Sell	11,936 -1,596	-12%	-$10.8K	﹤0.01%	2929
2019 Q3	$100K	Buy	+13,532	New	+$133K	﹤0.01%	2977
2018 Q3	–	Sell	-9,718	Closed	-$222K	–	2556
2018 Q2	$222K	Buy	+9,718	New	+$248K	﹤0.01%	2404

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

HSBC Holdings's CTMX Position: Q2 2026 in Review

HSBC Holdings opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 26,636 shares worth $103K. The stake represents ﹤0.01% of the portfolio and ranks #2803 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in CTMX as recently as Q4 2025.

HSBC Holdings first reported a position in CTMX in Q2 2018 and has held it in 9 quarters since. The position peaked at $222K in Q2 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

HSBC Holdings held 26,636 shares of CytomX Therapeutics worth $103K as of Q2 2026.
CytomX Therapeutics was a new HSBC Holdings position in Q2 2026.
CytomX Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2803 holding.
HSBC Holdings first reported a position in CytomX Therapeutics in Q2 2018 and has held it in 9 quarters since.
HSBC Holdings's CytomX Therapeutics position peaked at $222K in Q2 2018.
179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.